We have compared the anaesthetic and analgesic efficacy of levobupivacaine with that of racemic bupivacaine in 66 male patients undergoing ambulatory primary inguinal herniorrhaphy. Patients were allocated randomly in a double-blind manner to local infiltration anaesthesia (0.25%w/v 50 ml) with either racemic bupivacaine (nϭ33) or levobupivacaine (nϭ33). Scores for intraoperative pain and satisfaction with anaesthesia were recorded, together with perception of postoperative pain and need for supplementary postoperative analgesic medications in the first 48 h after operation. Intraoperative satisfaction with the infiltration anaesthesia was similar, with median scores of 77 (levobupivacaine) and 80 (bupivacaine) (VAS; 100 mmϭ extremely satisfied). Time averaged postoperative pain scores (48 h) were 8 (levobupivacaine) and 10 (bupivacaine) in the supine position, 13 (levobupivacaine) and 12 (bupivacaine) while rising from the supine position to sitting, and 9 (levobupivacaine) and 13 (bupivacaine) while walking (VAS; 100 mmϭworst pain imaginable) (ns). There was no difference in the use of peroral postoperative analgesics between the two groups. We conclude that racemic bupivacaine and its S-enantiomer levobupivacaine had similar efficacy when used as local infiltration anaesthesia in inguinal herniorrhaphy.
Infiltration anaesthesia with bupivacaine in herniorrhaphy is a safe procedure, with a low risk of cardiac and neurological toxic effects related to unintentional intravascular injection. Experimental data from small mammals 1 suggest that levobupivacaine (S-enantiomer) is less toxic than racemic bupivacaine, but there are no comparative studies of efficacy for infiltration anaesthesia.
The aim of this study was to compare intra-and postoperative pain relief of levobupivacaine with that of racemic bupivacaine when used for infiltration anaesthesia in inguinal herniorrhaphy.
Methods and results
The study took place from April 1997 to October 1997. We studied 66 male patients, aged 30-80 yr, ASA I-II, undergoing primary elective inguinal repair under infiltration anaesthesia on an outpatient basis. The study was approved by the Local Ethics Committee and written, informed consent was obtained from each patient.
Patients were allocated randomly, on the basis of com-© British Journal of Anaesthesia puter-generated tables, in a double-blind manner, to receive either racemic bupivacaine (nϭ33) or levobupivacaine (nϭ33) as infiltration anaesthesia. Patients received midazolam 2 mg as intraoperative sedation, which could be supplemented with up to 3 mg. Patients were monitored continuously with intraoperative ECG and pulse oximetry. Infiltration anaesthesia with 50 ml of 0.25% bupivacaine hydrochloride or 50 ml of 0.25% levobupivacaine base was given according to a strict protocol, with preoperative injection of 20 ml intracutaneously, subcutaneously and in the deeper layers under the planned line of skin incision. During operation, 20 ml of the test substance were administered subfascially, near the pubic tuberculum and around the inguinal cord at the deep inguinal ring. An additional 10 ml of local anaesthetic were used, at the latest just before closure of the oblique external fascia. If needed, an additional 10 ml was used during operation. A Lichtenstein mesh repair was used for a direct inguinal hernia and a Lichtenstein mesh repair or annulorrhaphy for an indirect inguinal hernia.
Immediately after operation, patients were asked to score intraoperative pain on a global verbal rating scale and to assess satisfaction with anaesthesia on a 100-mm visual analogue scale (VAS). After operation, patients received ibuprofen tablets 600 mg up to three times a day, as needed, and were asked to record intake of ibuprofen in addition to intake of any additional analgesics. The degree of postoperative pain was established on a 100-mm VAS scale (0ϭno pain, 100ϭworst pain imaginable) while supine, while rising from the supine position to sitting and while walking, at 1, 2, 3, 4, 8, 12, 24 and 48 h after operation. Patients were discharged 4 h after operation with a diary card to be returned 48 h after operation. For all postoperative VAS measurements, an average VAS score (A-VAS) for each patient was obtained by dividing the area under the VAS vs time curve by the actual observation time. Intake of ibuprofen was accumulated for each patient, and average hourly intake was calculated. Patient characteristics were compared using the Wilcoxon rank sum test or Fisher's exact test. A-VAS, VAS for satisfaction with anaesthesia and intake of ibuprofen were compared using the Wilcoxon rank sum test, with 95% confidence intervals on difference in medians calculated. 2 Differences between the two groups on global verbal rating and need for additional analgesics after operation were compared using Fisher's exact test. All calculations were performed using SAS software, version 6.12. Actual P values are given and PϽ0.05 was considered significant.
There were no significant differences in age, weight, ratio of direct/indirect hernias or duration of surgery between the two groups. Twelve patients who received levobupivacaine (36%) reported moderate or severe intraoperative pain, compared with seven (21%) in the bupivacaine group 281 (ns). In both groups, median use of midazolam was 2 mg. There was no difference between groups (ns) for VAS score regarding satisfaction with anaesthesia. In both groups, the score was well above the middle of the VAS scale, showing a high level of patient acceptance of this type of anaesthesia.
Three patients who received levobupivacaine and five who received bupivacaine needed additional intraoperative local anaesthetic to supplement the 50-ml standard infiltration anaesthesia, but all 66 patients were operated on using the 60-ml limit, corresponding to 150 mg of bupivacainelevobupivacaine.
Median values for A-VAS are shown in Table 1 for patients in the supine position, on moving from the supine position to sitting, and while walking. A-VAS scores were almost identical in the two groups for all assessments. The 95% confidence limits for all A-VAS scores showed that the largest possible difference was approximately 10 mm.
There was no difference in the need for postoperative ibuprofen. A similar proportion of patients needed additional analgesics (morphine/paracetamol) as a supplement to ibuprofen. Three patients had complications within 48 h after operation which required treatment: two patients (one in each group) developed intraoperative bradycardia (both with heart rate less than 30 beat min -1 ) and one patient who received levobupivacaine developed a postoperative haematoma requiring reoperation.
Comment
Our results showed nearly identical A-VAS scores between the bupivacaine and levobupivacaine groups when used for infiltration anaesthesia in inguinal hernia repair. As the largest possible difference (95% confidence limits) in A-VAS score was only approximately 10 mm, a clinically relevant difference in intra-and postoperative analgesia was considered unlikely. These findings during infiltration anaesthesia are similar to those comparing racemic bupivacaine with levobupivacaine in epidural anaesthesiaanalgesia. 3 With regard to the safety of the S-isomer of bupivacaine, our study was too small to allow any conclusions to be drawn. Two patients (one in each group) developed bradycardia during surgery, which may have been related to manipulation and traction on the spermatic cord.
In summary, we conclude that the clinical efficacy of 282 levobupivacaine and racemic bupivacaine was similar when used for infiltration anaesthesia in inguinal herniorrhaphy.
